Tacrolimus-Induced Thrombotic Microangiopathy After Orthotopic Heart Transplant: A Case Report

Tacrolimus (FK 506) is a calcineurin inhibitor and is commonly used as an immunosuppressant after a solid organ transplant. One of the serious adverse effects of tacrolimus is thrombotic microangiopathy (TMA) which has a high mortality rate. TMA leads to vascular thrombosis, eventually leading to is...

Descripción completa

Detalles Bibliográficos
Autores principales: Gill, Rajwinder, Meghrajani, Vineet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Cardiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9275527/
https://www.ncbi.nlm.nih.gov/pubmed/35836452
http://dx.doi.org/10.7759/cureus.25874
Descripción
Sumario:Tacrolimus (FK 506) is a calcineurin inhibitor and is commonly used as an immunosuppressant after a solid organ transplant. One of the serious adverse effects of tacrolimus is thrombotic microangiopathy (TMA) which has a high mortality rate. TMA leads to vascular thrombosis, eventually leading to ischemia of end organs. It is diagnosed clinically and based on the laboratory parameters. Early detection of TMA and prompt treatment can change the course. Drug-induced TMA has a poor prognosis as compared to idiopathic TMA. We present here the case of a 47-year-old male who developed tacrolimus-induced TMA after an orthotopic heart transplant and he was treated with the currently available treatment. He ultimately died after 40 days of hospitalization. 

Ejemplares similares